Treatment for Chronic Lymphocytic Leukemia

Phase-Based Progress Estimates
Northwell (Northshore University/Long Island Jewish Hospitals), New Hyde Park, NYChronic Lymphocytic Leukemia+4 More
All Sexes
What conditions do you have?

Study Summary

This trial will track patients starting a new drug to see if it causes heart rhythm problems. Action taken if problems occur will be noted.

Eligible Conditions
  • Chronic Lymphocytic Leukemia
  • Atrial Fibrillation
  • Supraventricular Tachycardia (SVT)
  • Ventricular Arrhythmias and Cardiac Arrest
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: at 18 months after start of BTK inhibitor

Month 18
Incidence of device detected atrial fibrillation (AF)
Incidence of device detected ventricular arrhythmia (VA)
Month 60
BTK dose reduction or discontinuation due to device detected arrhythmia, assessed by chart review.
Initiation of anticoagulation for AF detected by device monitoring, assessed by chart review
Long term Incidence of device detected AF
Long term incidence of device detected ventricular arrhythmia (VA)

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

50 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at 18 months after start of btk inhibitor

Who is running the clinical trial?

Northwell HealthLead Sponsor
426 Previous Clinical Trials
462,373 Total Patients Enrolled
Robert S Copeland-Halperin, MDPrincipal InvestigatorNorthwell Health
Haisam Ismail, MDPrincipal InvestigatorNorthwell Health

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are okay with being monitored from a distance.